NCT00364286View on ClinicalTrials.gov

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

PHASE2CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

LeukemiaLymphoma

Interventions

DRUG

Dasatinib (BMS-354825)

50mg Orally twice daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER